Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.
OBJECTIVE
To define the role of intravitreal bevacizumab in individuals with choroidal neovascularization (CNV) resulting from Ocular Histoplasmosis syndrome (OHS).


METHODS
Retrospective chart review of a surgical therapy.


METHODS
We reviewed the course of 28 eyes of 28 patients who underwent intravitreal injection of bevacizumab for treatment of CNV secondary to OHS. Outcome was measured by pretreatment and posttreatment visual acuity (VA).


RESULTS
The average pretreatment logarithm of the minimum angle of resolution (logMAR) VA was 0.65 (Snellen equivalent of 20/88). Mean follow-up was 22.43 weeks with an average of 1.8 intravitreal injections. Average final logMAR VA was 0.43 (Snellen equivalent of 20/54). Twenty eyes (71%) experienced an increase in central VA, whereas four eyes (14%) were unchanged and four eyes (14%) experienced a decrease in vision.


CONCLUSIONS
Intravitreal bevacizumab may improve or stabilize VA in a significant majority of patients with neovascular complications of OHS (24 eyes [85.7%] in our study population).
Schadlu
Ramin
R
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri, USA.
Blinder
Kevin J
KJ
Shah
Gaurav K
GK
Holekamp
Nancy M
NM
Thomas
Matthew A
MA
Grand
M Gilbert
MG
Engelbrecht
Nicholas E
NE
Apte
Rajendra S
RS
Joseph
Daniel P
DP
Prasad
Anita G
AG
Smith
Bradley T
BT
Sheybani
Arsham
A
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D015821:Eye Infections, Fungal / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006658:Histoplasma / Q000302:isolation & purification; D006660:Histoplasmosis / Q000150:complications*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab